摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-[(17-Hydroxy-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthren-3-yl)oxy]acetic acid | 41164-36-7

中文名称
——
中文别名
——
英文名称
2-[(17-Hydroxy-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthren-3-yl)oxy]acetic acid
英文别名
——
2-[(17-Hydroxy-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthren-3-yl)oxy]acetic acid化学式
CAS
41164-36-7
化学式
C20H26O4
mdl
——
分子量
330.424
InChiKey
DFDLVUUNTZHQBI-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    214-215 °C
  • 沸点:
    516.5±50.0 °C(Predicted)
  • 密度:
    1.226±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    2.6
  • 重原子数:
    24
  • 可旋转键数:
    3
  • 环数:
    4.0
  • sp3杂化的碳原子比例:
    0.65
  • 拓扑面积:
    66.8
  • 氢给体数:
    2
  • 氢受体数:
    4

安全信息

  • 危险品标志:
    Xn
  • 安全说明:
    S22,S36
  • 危险类别码:
    R20/21/22,R40

SDS

SDS:8bd9e4193c42ab1f21d5573110400ced
查看

文献信息

  • [EN] GLUCAGON SUPERFAMILY PEPTIDES EXHIBITING GLUCOCORTICOID RECEPTOR ACTIVITY<br/>[FR] PEPTIDES DE LA SUPERFAMILLE DU GLUCAGON PRÉSENTANT UNE ACTION SUR LES RÉCEPTEURS AUX GLUCOCORTICOÏDES
    申请人:UNIV INDIANA RES & TECH CORP
    公开号:WO2013074910A1
    公开(公告)日:2013-05-23
    Provided herein are glucagon superfamily peptides conjugated with GR ligands that are capable of acting at a glucocorticoid receptor. Also provided herein are pharmaceutical compositions and kits of the conjugates of the invention. Further provided herein are methods of treating a disease, e.g., a metabolic disorder, such as diabetes and obesity, comprising administering the conjugates of the invention.
    本文提供了与GR配体结合的葡萄糖素超家族肽,这些肽能够作用于糖皮质激素受体。本文还提供了该发明的结合物的药物组合物和工具包。此外,本文还提供了治疗疾病的方法,例如代谢紊乱,如糖尿病和肥胖,包括给予该发明的结合物。
  • GLUCAGON SUPERFAMILY PEPTIDES EXHIBITING NUCLEAR HORMONE RECEPTOR ACTIVITY
    申请人:Indiana University Research and Technology Corporation
    公开号:EP2569000B1
    公开(公告)日:2017-09-27
  • GLUCAGON SUPERFAMILY PEPTIDES EXHIBITING GLUCOCORTICOID RECEPTOR ACTIVITY
    申请人:Indiana University Research and Technology Corporation
    公开号:EP2780031B1
    公开(公告)日:2018-03-07
  • METHOD FOR DETECTION OF FLUORIDE OR HYDROGEN FLUORIDE AND DETECTION KIT
    申请人:Ezan Eric
    公开号:US20080248593A1
    公开(公告)日:2008-10-09
    The present invention relates to a method for detecting and/or measuring the concentration of fluoride (F − ) or hydrogen fluoride (HF) in a sample, comprising the steps consisting of bringing said sample, in aqueous solution, into contact with a silylated organic compound in order to obtain a measurement solution, with said silylated organic compound being desilylated when it is in the presence of hydrofluoric acid or a fluoride, with the silylated organic compound and the desilylated organic compound being able to be detected and/or measured separately from each other; and detecting and/or measuring, in said measurement solution, the appearance of the desilylated against compound or the disappearance of the silylated organic compound, which takes place if fluoride or hydrogen fluoride is present in the sample. The method enables the presence of hydrogen fluoride or of fluorine to be detected very easily and expediently at concentrations of 10 −2 l of HF/10 6 l of air (10 ppb) or else of 0.5 to 1 μg/ml of HF in solution. The kit of the present invention comprises the components which are required for implementing this method. The method of the invention makes it possible to detect fluorine at concentrations of the order of 0.001 μg/ml.
  • Glucagon Superfamily Peptides Exhibiting Glucocorticoid Receptor Activity
    申请人:Indiana University Research and Technology Corp
    公开号:US20130157934A1
    公开(公告)日:2013-06-20
    Provided herein are glucagon superfamily peptides conjugated with GR ligands that are capable of acting at a glucocorticoid receptor. Also provided herein are pharmaceutical compositions and kits of the conjugates of the invention. Further provided herein are methods of treating a disease, e.g., a metabolic disorder, such as diabetes and obesity, comprising administering the conjugates of the invention.
查看更多